Pipeline Expansion

CRISPR Therapeutics continues to broaden its pipeline through collaborations with Vertex and Sirius Therapeutics. New candidates include CTX310 (cardiovascular), CTX611 (thromboembolic), a refractory hypertension therapy, treatments for alpha‑1 antitrypsin deficiency affecting lung and liver disease, and several autoimmune disease indications. The company’s recent equity raise has added capital but also underscores the ongoing risk associated with heavy R&D spending and dependence on milestone achievements for both product development and commercialization.